Several newly approved agents for asthma together with others seeking approval are expanding the range of therapeutic options for this disease in Brazil and Mexico. Drugs such as the inhaled…
Tens of millions of people in the United States have a lipid abnormality or dyslipidemia. Given the inherent risk of cardiovascular disease that dyslipidemias carry, multiple prescription therapies…
With more than 32 million people in the United States diagnosed with osteoarthritis (OA), it is the most common type of arthritis and a leading cause of disability. Among the symptoms…
High unmet need exists for severe, refractory asthma patients, for whom Genentech/Novartis’s Xolair is currently the only therapeutic option. Together with a number of newly approved agents for…
The launch of novel oral anticoagulants (NOACs), such as Bayer/Janssen’s Xarelto, Bristol-Myers Squibb/Pfizer’s Eliquis/Elicuis, and Boehringer Ingelheim’s Pradaxa/Pradaxar, in Brazil and…
The syndicated ChartTrends: Multiple Sclerosis (US) report allows clients to better understand the actual treatment of multiple sclerosis (MS) with disease-modifying therapies (DMTs) through…
In 2013, Brazil’s total pharmaceutical market for type 2 diabetes rivaled the size of some of the major markets. Increasing public awareness, an aging population, and the launch of new premium-…
A gradual decline in testosterone is a natural part of the aging process in men. However, when testosterone falls below normal levels and when related symptoms, such as erectile dysfunction,…
Do Physicians Have High Hopes for LDL-Lowering Therapies in Cardiovascular Outcomes? As one of the most prevalent diseases in the major pharmaceutical markets, dyslipidemia represents a compelling…
Do Physicians Have High Hopes for LDL-Lowering Therapies in Cardiovascular Outcomes? As one of the most prevalent diseases in the major pharmaceutical markets, dyslipidemia represents a compelling…
In a Market Dominated by Effective TNF-Alpha Inhibitors for Moderate to Severe Disease, Where Do Physicians and Payers See Viable Areas for Differentiation? Ankylosing spondylitis (AS) is a…
In a Market Dominated by Effective TNF-Alpha Inhibitors for Moderate to Severe Disease, Where Do Physicians and Payers See Viable Areas for Differentiation? Ankylosing spondylitis (AS) is a…
The era of personalized medicine is already well established in oncology. Biomarker-driven targeted therapies are among the top-selling oncology products today, and the impact of molecular…
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite the drug development process for promising novel therapies for serious or life-threatening conditions. In 2013, of 28…
Alzheimer’s disease (AD) is one of the most common neurological conditions in the elderly and imparts considerable strain on worldwide healthcare resources. For the estimated 2 million people in…